These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16472241)

  • 1. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Matthews EJ; Kruhlak NL; Weaver JL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Dec; 1(4):243-54. PubMed ID: 16472241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.
    Ursem CJ; Kruhlak NL; Contrera JF; MacLaughlin PM; Benz RD; Matthews EJ
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):1-22. PubMed ID: 19422096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Ursem CJ; Kruhlak NL; Benz RD; Sabaté DA; Yang C; Klopman G; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):23-42. PubMed ID: 19422098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
    Matthews EJ; Frid AA
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Kruhlak NL; Benz RD; Aragonés Sabaté D; Marchant CA; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):43-65. PubMed ID: 19422100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
    Frid AA; Matthews EJ
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):276-89. PubMed ID: 19941924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
    Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
    Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.
    Matthews EJ; Kruhlak NL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Jan; 1(1):61-76. PubMed ID: 16472220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices.
    Contrera JF; Matthews EJ; Daniel Benz R
    Regul Toxicol Pharmacol; 2003 Dec; 38(3):243-59. PubMed ID: 14623477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of spontaneous adverse drug reaction (ADR) reports using supplementary information.
    Ghosh P; Dewanji A
    Stat Med; 2011 Jul; 30(16):2040-55. PubMed ID: 21544847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.
    Harpaz R; Haerian K; Chase HS; Friedman C
    AMIA Annu Symp Proc; 2010 Nov; 2010():281-5. PubMed ID: 21346985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's sentinel network: a monumental task.
    Young D
    Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
    [No Abstract]   [Full Text] [Related]  

  • 16. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of systemic hypersensitivity to drugs using standard guinea pig assays.
    Weaver JL; Staten D; Swann J; Armstrong G; Bates M; Hastings KL
    Toxicology; 2003 Dec; 193(3):203-17. PubMed ID: 14599760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection.
    Trifirò G; Patadia V; Schuemie MJ; Coloma PM; Gini R; Herings R; Hippisley-Cox J; Mazzaglia G; Giaquinto C; Scotti L; Pedersen L; Avillach P; Sturkenboom MC; van der Lei J; Eu-Adr Group
    Stud Health Technol Inform; 2011; 166():25-30. PubMed ID: 21685607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.